Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α₁-antitrypsin-derived peptide motif.

ABSTRACT: Targeted drug delivery to disease-associated activated neutrophils can provide novel therapeutic opportunities while avoiding systemic effects on immune functions. We created a nanomedicine platform that uniquely utilizes an α₁-antitrypsin-derived peptide to confer binding specificity to neutrophil elastase on activated neutrophils. Surface decoration with this peptide enabled specific anchorage of nanoparticles to activated neutrophils and platelet-neutrophil aggregates, in vitro and in vivo. Nanoparticle delivery of a model drug, hydroxychloroquine, demonstrated significant reduction of neutrophil activities in vitro and a therapeutic effect on murine venous thrombosis in vivo. This innovative approach of cell-specific and activation-state-specific targeting can be applied to several neutrophil-driven pathologies.

SUBMITTER: Cruz MA 

PROVIDER: S-EPMC9909445 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature